www.ijcrt.org © 2022 IJCRT | Volume 10, Issue 4 April 2022 | ISSN: 2320-2882 IJCRT2204181 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org b495 Alzheimer’s Disease and role of GSK inhibitors Varun Ashish Shah 1 , Kenil Jiteshkumar Patel 1 , Dhruv Sanjaykumar Karelia 1 , Vraj Hitendrabhai Patel 1, SP Srinivas Nayak 2 , Gunosindhu Chakraborthy 3 1 Pharm.D, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India. 2 Department of Pharmacy Practice, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India. 3 Professor and Principal, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India. Abstract The global prevalence of dementia can be characterized by a progressive deterioration in cognition, function, behavior, considered as a neurodegenerative age-related disorder that can have genetic as well as non-geneticorigin. It can be considered multifactorial as only a limited number of cases supporting genetic theory have been identified. Alzheimer’s is a particularly captivating subject because of its number of causes and factors and increasing targets. Furthermore, the article discusses a few famous hypotheses that are believed for the progress of Alzheimer’sdisease, factors affecting and responsible for the development of this disease. Adding to it pharmacological, non-pharmacological as well as the ayurvedic perspective has been deliberated. It briefly presents glycogen synthase inhibitors as new targets for AD and explains how it is related to this disease and how it can bring a huge alteration in the treatment of AD by providing appropriate proof and theories supporting the same. Key words: Alzheimer’s, dementia, treatment, risk factors, amyloid, tau, hypothesis, mitochondria, Ayurveda 1. Introduction to Alzheimer and GSK inhibitors Alzheimer’s disease is considered to be the most common cause and most prevailing dementia which escalated up to 44 million population in 2015 and was predicted to be quadruple by 2050. The estimated cost for the treatment of this disease was $172 billion per year also Alzheimer’s is particularly fascinating because itattempts to harness the true complexity of pathology and how molecular variation can affect how neurons interact with one another on a grander scale. (1) Even though there is no certain treatment to cure AD there are treatments that can reduce the progression of disease and worsening of dementia symptoms and the drugs and treatments were decided based on the hypothesis mentioned below in the article also GSK3β inhibitors have been identified as novel target s